UK Approves Eli Lilly's Oral Weight-Loss and Diabetes Drug Foundayo
The UK has become the first European country to approve Eli Lilly's oral weight-loss and type 2 diabetes drug, Foundayo (orforglipron). Approved by the Medicines and Healthcare products Regulatory Agency, the once-daily pill will launch privately later this month but is not yet available through the NHS. This approval follows Novo Nordisk's Wegovy, another GLP-1 treatment, intensifying competition in the expanding oral weight-loss drug market alongside established injectable therapies.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (58/100). Lens Score 49/100.
Outlets measured: economictimes, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–62/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 11 Aug, 02:21 am. Other outlets followed.
- 1